Viewing nowCombinationDURAB Tablet 30/2.5 mg (Pimasartan Potassium, Esamlodipine)
Fimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Nexpharm Korea Co., Ltd.

MFDS item code 202300087 · Approved 2023.01.06
Treatment of essential hypertension not adequately controlled with fimasartan monotherapy
Used in patients with essential hypertension when blood pressure is not sufficiently controlled by monotherapy with Pimasartan Potassium.
Adults The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose of fimasartan; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams as monotherapy. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy or with this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is necessary for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be started with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication can cause serious injury or death to the fetus or newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to the main ingredients of this medication or similar drugs, those who are pregnant or breastfeeding, patients undergoing renal dialysis, patients with severely impaired liver function, those with biliary obstruction, certain kidney diseases or diabetes, those with lactose intolerance, patients with severe aortic stenosis, and those in a state of shock should not take this medication. Caution should be exercised when using this medication in patients with a deficient blood volume or low salt levels, impaired renal function, renal artery hypertension, patients with aortic or mitral valve stenosis, primary hyperaldosteronism, severe hypotension, the elderly, and those with allergies to certain pigments, as their condition should be closely monitored. Adverse effects such as dizziness, headache, facial or peripheral edema, urination disorders, insomnia, and flushing may occur; consult a physician if any unusual symptoms arise. There is a risk of serious adverse effects such as sudden drops in blood pressure, severe allergic reactions, and worsening renal function; therefore, caution is necessary. This medication can interact with other antihypertensive agents, diuretics, potassium-sparing drugs, certain anti-inflammatory drugs, antibiotics, lithium, grapefruit juice, etc.; notify your healthcare provider of all medications you are currently taking. It is advisable to avoid taking this medication during pregnancy or breastfeeding, but if necessary, consult a physician thoroughly. The safety and efficacy of this medication in children or adolescents under 18 years of age have not been established. No special dose adjustment is needed for elderly patients, but caution is advised due to potential sensitivity reactions. Patients with severely impaired liver function should not take this medication. In case of overdose, symptoms such as hypotension, palpitations, and in severe cases, shock may occur; immediate medical attention is necessary. This medication should be kept out of reach of children, and transferring it to another container may result in degradation of quality or accidental exposure, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to light and should be stored in a tightly closed container that blocks light. It is important to maintain the storage temperature between 1 to 30 degrees Celsius to preserve the drug's effectiveness and safety for an extended period.
White film-coated tablets with rounded edges
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Nexpharm Korea Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.